Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription 11.05.2026 1 Acta Neuropathol 1 Alzheimer Dis Assoc Disord 11 Alzheimers Dement 1 Am J Alzheimers Dis Other Demen 1 Ann Neurol 1 Brain 3 Brain Res 7 Curr Alzheimer Res 1 Exp Neurol 12 J Alzheimers Dis 1 J Am Geriatr Soc 1 J Neural Transm (Vienna) 1 J Neurol 1 Nat Rev Neurol 1 Neurochem Res 2 Neurologia (Engl Ed) 4 Neurology 2 Neurosci Lett 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Neuropathol

1. ROBINSON JL, Cai H, Loh NJ, Vazquez O, et al
   Idiotypic-susceptible Alzheimer's disease: a clinically relevant, neurofibrillary tangle subtype.
   Acta Neuropathol. 2026;151:51.
   PubMed         Abstract available
   
   

   
   Alzheimer Dis Assoc Disord

2. BAE Y, Kim M, Jeon SR, Lee SW, et al
   Risk of Alzheimer Disease and Other Dementias in Patients With Parkinson Disease: A Nationwide Cohort Study.
   Alzheimer Dis Assoc Disord. 2026 May 6. doi: 10.1097/WAD.0000000000000722.
   PubMed         Abstract available
   
   

   
   Alzheimers Dement

3. BUTLER CA, Gee MS, O'Gara K, Milinkeviciute G, et al
   Abi3(S212F) Alzheimer's disease variant alters plaque structure and disrupts microglia.
   Alzheimers Dement. 2026;22:e71452.
   PubMed         Abstract available
   
   
4. BURKETT BJ, Wiste HJ, Johnson DR, Boeve BF, et al
   Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.
   Alzheimers Dement. 2026;22:e71449.
   PubMed         Abstract available
   
   
5. GABEL M, Goswami S, Bekena S, Solomon ED, et al
   The impact of learning about financial compensation on enrollment in Alzheimer's disease longitudinal research.
   Alzheimers Dement. 2026;22:e71356.
   PubMed         Abstract available
   
   
6. BOUTAJANGOUT A, Masurkar AV, Osorio R, Debure L, et al
   Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.
   Alzheimers Dement. 2026;22:e71441.
   PubMed         Abstract available
   
   
7. HWANG J, Pyun JM, Lee JY, Park JS, et al
   Integrating polygenic and transcriptional risk scores for detecting Alzheimer's disease.
   Alzheimers Dement. 2026;22:e71408.
   PubMed         Abstract available
   
   
8. HOFMANN A, Saef B, Powell WJB, Paczynski M, et al
   Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.
   Alzheimers Dement. 2026;22:e71442.
   PubMed         Abstract available
   
   
9. PURI S, van der Spek SJF, Lin M, Wang Z, et al
   circPDE4B downregulation triggers GEMIN5?dependent translational stress response and autophagy to reduce MAPT pathology.
   Alzheimers Dement. 2026;22:e71436.
   PubMed         Abstract available
   
   
10. VAN METER TE, Wilson EN, Elahi F, Rissman RA, et al
    Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup.
    Alzheimers Dement. 2026;22:e71252.
    PubMed         Abstract available
    
    
11. TANG C, Yang J, Lei X, He D, et al
    Reply to: Beyond AUC: Advancing clinical interpretability of depression-MRI-machine learning analyses in Alzheimer's disease.
    Alzheimers Dement. 2026;22:e71439.
    PubMed        
    
    
12. WINER JR, Plastini MJ, Romero A, Vossler H, et al
    Effects of alpha-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging.
    Alzheimers Dement. 2026;22:e71455.
    PubMed         Abstract available
    
    
13. LI K, Shacham E, Zhu Y, Trani JF, et al
    Driving the neural exposome: Latent mobility states from naturalistic GPS data in older adults.
    Alzheimers Dement. 2026;22:e71425.
    PubMed         Abstract available
    
    

    
    Am J Alzheimers Dis Other Demen

14. STITES SD, Kuz C, Largent EA, Harkins K, et al
    Four Common Beliefs About Patient Memory Evaluations: Who Has Them and What Modifies Them?
    Am J Alzheimers Dis Other Demen. 2026;41:15333175261447038.
    PubMed         Abstract available
    
    

    
    Ann Neurol

15. JIANG X, O'Bryant SE, Rissman RA, Johnson LA, et al
    Multimorbidity and Associations with Cognition and Alzheimer's Disease Biomarkers.
    Ann Neurol. 2026 May 4. doi: 10.1002/ana.78238.
    PubMed         Abstract available
    
    

    
    Brain

16. GAWOR K, Statz K, Schaeverbeke J, Thal DR, et al
    Alzheimer's disease subtyping approaches and the role of co-pathologies.
    Brain. 2026 May 4:awag157. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Brain Res

17. CHEN W, Su F, Kong H, Wang Y, et al
    APOE genotype and astrocyte activity collectively influence AD biomarkers and Abeta burden.
    Brain Res. 2026;1883:150283.
    PubMed         Abstract available
    
    
18. MATUSZEWSKA M, Cieslik M, Sulejczak D, Wilkaniec A, et al
    BET protein inhibitor JQ1 reduces inflammationand hippocampal amyloid-beta level without altering Tau phosphorylation in LPS-challenged adult wild-type mice.
    Brain Res. 2026;1884:150318.
    PubMed         Abstract available
    
    
19. SARKO LE, Klaus E, Bondarenko V, Secker C, et al
    uPAR exhibits age- and region-dependent expression in the brains of mice with Alzheimer's disease-like pathology.
    Brain Res. 2026;1886:150364.
    PubMed         Abstract available
    
    

    
    Curr Alzheimer Res

20. YOSHIDA H, Inoue T, Suzuki S, Tomata Y, et al
    Sodium-to-Potassium Ratio and Alzheimer's Disease: A Mendelian Randomization Study.
    Curr Alzheimer Res. 2026 Apr 23. doi: 10.2174/0115672050472115260421093303.
    PubMed         Abstract available
    
    
21. ZHANG Y, Tong S, Chen Y, Li C, et al
    An Inverse Association Between the Composite Dietary Antioxidant Index and Alzheimer's Disease: Evidence from an NHANES-Based Cross-Sectional Study.
    Curr Alzheimer Res. 2026 Apr 23. doi: 10.2174/0115672050462427260407045906.
    PubMed         Abstract available
    
    
22. KURMI S, Shirodkar S, Parab SB, Doshi G, et al
    A Multimodal Framework for Alzheimer's Prevention: Diet, Exercise, Fasting, Sleep, and Gut Microbiota.
    Curr Alzheimer Res. 2026 May 5. doi: 10.2174/0115672050467997260323164241.
    PubMed         Abstract available
    
    
23. LI Y, Li L, Yang Q, Xiong J, et al
    Comparative Efficacy and Safety of Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Curr Alzheimer Res. 2026 May 5. doi: 10.2174/0115672050437623260417063631.
    PubMed         Abstract available
    
    
24. NAYAK RK, Mohapatra SR, Sahoo SK, Sahu SK, et al
    Gut Microbiota Dysbiosis in Alzheimer's Disease and Possible Therapeutic Options.
    Curr Alzheimer Res. 2026 May 4. doi: 10.2174/0115672050448298260303052535.
    PubMed         Abstract available
    
    
25. YANG Y, Huang X, Liu H, Yu C, et al
    The Role of Ectopic Fat in Alzheimer's Disease.
    Curr Alzheimer Res. 2026 May 5. doi: 10.2174/0115672050461650260406064722.
    PubMed         Abstract available
    
    
26. CHAUDHARI DB, Barve K
    Targeting Shared Mechanisms in Atherosclerosis and Alzheimer's Disease.
    Curr Alzheimer Res. 2026 May 5. doi: 10.2174/0115672050447493260327074829.
    PubMed         Abstract available
    
    

    
    Exp Neurol

27. DELONCLE R
    Conjecture for a free radical epimerization process in Alzheimer, Parkinson, Lewy body, amyotrophic lateral sclerosis, progressive Supranuclear Palsy and Creutzfeldt Jakob diseases.
    Exp Neurol. 2026 May 5:115812. doi: 10.1016/j.expneurol.2026.115812.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

28. GUPTA A, Anjali A, Adhya A, Vetal D, et al
    Clinical relevance of automated cerebrospinal fluid amyloid and tau biomarkers in Indian patients with early onset cognitive decline: Insights from the AIIMS-Delhi Study Cohort of Early/late oNset Dementia (ASCEND).
    J Alzheimers Dis. 2026;111:142-148.
    PubMed         Abstract available
    
    
29. AL-HAMMADI M, Fleyeh H, Thomas I
    Gait and movement analysis for discrimination between people with dementia and healthy control persons based on pose estimation and machine learning.
    J Alzheimers Dis. 2026;111:222-239.
    PubMed         Abstract available
    
    
30. LI Y, Feng J, Xie Y, Yao Q, et al
    Eye-brain coupling-mediated eye movement abnormalities as non-invasive biomarkers for mild cognitive impairment: A systematic review.
    J Alzheimers Dis. 2026;111:90-101.
    PubMed         Abstract available
    
    
31. WEI X, Li T, Yang N, Xu K, et al
    Distinct morphological patterns of the hippocampus and amygdala in normal and pathological aging.
    J Alzheimers Dis. 2026;111:433-453.
    PubMed         Abstract available
    
    
32. STEWART PV, Boscarino JJ
    Non-linear demographic correction enhances the diagnostic utility of the Montreal Cognitive Assessment.
    J Alzheimers Dis. 2026;111:294-300.
    PubMed         Abstract available
    
    
33. DHARESHWAR S, Kane M, Lewis C, Mineur R, et al
    Update on the current state of speech and language testing in Alzheimer's disease.
    J Alzheimers Dis. 2026 May 4:13872877261446637. doi: 10.1177/13872877261446637.
    PubMed         Abstract available
    
    
34. BASCHE K, He D, Langhough R, Jonaitis E, et al
    Validation of longitudinal change in proper name recall with pTau217 as a marker of early cognitive decline in cognitively unimpaired adults at risk for Alzheimer's disease dementia.
    J Alzheimers Dis. 2026 May 4:13872877261446477. doi: 10.1177/13872877261446477.
    PubMed         Abstract available
    
    
35. MARZO RR, Li M, Yang Q, Chen H, et al
    Projected burden of Alzheimer's disease and other dementias in the Western Pacific, 2023-2050.
    J Alzheimers Dis. 2026 May 4:13872877261441774. doi: 10.1177/13872877261441774.
    PubMed         Abstract available
    
    
36. ALAM T, Rajdeep D, Kamal S, Osman Abufatima I, et al
    Trends in Alzheimer's disease mortality with metabolic syndrome-related conditions among older adults in the United States, 1999-2020.
    J Alzheimers Dis. 2026 May 4:13872877261445035. doi: 10.1177/13872877261445035.
    PubMed         Abstract available
    
    
37. MAHMOUDI F, Yazdan Panah M, Dehghani Firouzabadi D, Vaheb S, et al
    Choroid plexus volume in Alzheimer's disease: A systematic review and meta-analysis.
    J Alzheimers Dis. 2026 May 4:13872877261447404. doi: 10.1177/13872877261447404.
    PubMed         Abstract available
    
    
38. NAH S, Chek CJ, Montoya A, Duarte A, et al
    Health behavior mechanisms linking childhood socioeconomic status to Alzheimer's disease and related dementia risk: Exploring gender and racial/ethnic differences.
    J Alzheimers Dis. 2026 May 5:13872877251394317. doi: 10.1177/13872877251394317.
    PubMed         Abstract available
    
    
39. PEREIRA DA SILVA AM, Haddad Santos D
    Methodological considerations on the network meta-analysis of brexpiprazole dosing for agitation in Alzheimer's disease.
    J Alzheimers Dis. 2026 May 7:13872877261449394. doi: 10.1177/13872877261449394.
    PubMed        
    
    

    
    J Am Geriatr Soc

40. GRUDZEN CR, Brody AA, Chodosh J, Goldfeld KS, et al
    Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care.
    J Am Geriatr Soc. 2026 May 7. doi: 10.1111/jgs.70506.
    PubMed        
    
    

    
    J Neural Transm (Vienna)

41. KHALILI E, Sodaei F, Noroozian M, Sheldrick-Michel TM, et al
    Structural MRI in frontotemporal dementia and Alzheimer's disease: stage-dependent atrophy patterns.
    J Neural Transm (Vienna). 2026 May 4. doi: 10.1007/s00702-026-03158.
    PubMed         Abstract available
    
    

    
    J Neurol

42. HAFEZ MM, Abbas HA, Shoman NA, Soubh AA, et al
    A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease.
    J Neurol. 2026;273:303.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

43. TEUNISSEN CE, van Harten AC
    Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice.
    Nat Rev Neurol. 2026 May 6. doi: 10.1038/s41582-026-01215.
    PubMed        
    
    

    
    Neurochem Res

44. ZHENG X, Chen P, Li D, Li W, et al
    Lamotrigine Improves Spatial Learning and Attenuates AD-Related Pathology in APP/PS1 Mice, with Possible Involvement of the cAMP/PKA/CREB Pathway.
    Neurochem Res. 2026;51:149.
    PubMed         Abstract available
    
    

    
    Neurologia (Engl Ed)

45. AGUERO P, Gomez Tortosa E
    ADAM10 and its role in Alzheimer disease.
    Neurologia (Engl Ed). 2026 May 5:502083. doi: 10.1016/j.nrleng.2026.502083.
    PubMed         Abstract available
    
    
46. MOLINATTI F, De Gracia L, Oliva A
    Descriptive analysis of mortality due to Parkinson's disease and Alzheimer disease in Argentina.
    Neurologia (Engl Ed). 2026 May 1:502084. doi: 10.1016/j.nrleng.2026.502084.
    PubMed         Abstract available
    
    

    
    Neurology

47. CHUNG PA, Fleming VL, Reid KJ, Plante DT, et al
    Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome.
    Neurology. 2026;106:e214938.
    PubMed         Abstract available
    
    
48. FANG Y, Leng Y
    Can Targeting Circadian Rhythms Help Prevent Alzheimer Disease?: Lessons From Down Syndrome.
    Neurology. 2026;106:e218086.
    PubMed        
    
    
49. KNOPMAN DS
    Alzheimer Plasma Biomarkers in Mild Cognitive Impairment: Each With Distinct Etiologic and Prognostic Roles.
    Neurology. 2026;106:e218042.
    PubMed        
    
    
50. HAZAN J, Liu KY, Isaacs JD, Fox NC, et al
    What Does a Positive Alzheimer Disease Blood-Based Biomarker Result Mean in People With Mild Cognitive Impairment?
    Neurology. 2026;106:e214953.
    PubMed         Abstract available
    
    

    
    Neurosci Lett

51. DARZI M, Golchoobian R, Varzi HN, Shanehbandpour Tabari F, et al
    Metformin attenuates neurodegeneration in ICV-STZ-induced Alzheimer's model via antioxidant and anti-inflammatory mechanisms: implications for disease-modifying therapy.
    Neurosci Lett. 2026;880:138617.
    PubMed         Abstract available
    
    
52. SHAHSAVARI F, Rajizadeh MA, Pirmoradi Z, Sabzalizadeh M, et al
    Abscisic acid ameliorates cognitive deficits in an amyloid-beta-induced mouse model of Alzheimer's disease associated with alterations in markers of neuroplasticity and neuroinflammation.
    Neurosci Lett. 2026 May 5:138619. doi: 10.1016/j.neulet.2026.138619.
    PubMed         Abstract available
    
    

    
    PLoS One

53. YANG X
    Reducing annotation burden in medical imaging with ADGNET: A semi-supervised deep learning strategy.
    PLoS One. 2026;21:e0348596.
    PubMed         Abstract available
    
    
54. RAJAMOHAN HR, Xu Y, Zhu W, Kijowski R, et al
    Robust disease prognosis via diagnostic knowledge preservation: A sequential learning approach.
    PLoS One. 2026;21:e0344600.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum